Loading
A phase 2/3 trial of Abiraterone - Usual in prostate cancer, run by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair, active and no longer recruiting.
Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms is a phase 2/3 interventional study registered as NCT03348670 by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair, with 600 participants enrolled, started 2023-08-18 and due to reach its primary completion in 2026-11-18. Interventions recorded: Abiraterone - Usual and Abiraterone - Study.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Androgen deprivation & AR pathway inhibitors, Prostate cancer and the tag pipeline.
Shares Abiraterone acetate, Prostate cancer and the tag pipeline.
Shares Abiraterone acetate, Androgen deprivation & AR pathway inhibitors, Prostate cancer and the tag pipeline.
Shares Abiraterone acetate, Prostate cancer and the tag pipeline.
Shares Abiraterone acetate, Androgen deprivation & AR pathway inhibitors, Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/